ArticleBMC cardiovascular disorders2026
Predictive value of cardiometabolic index combined with N-Terminal pro-B-Type natriuretic peptide for moderate- to high-risk patients with acute coronary syndrome.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between the cardiometabolic index (CMI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and early risk stratification in patients with acute coronary syndrome (ACS), and to evaluate the predictive value of their combination for identifying intermediate- and high-risk patients.
methodsA retrospective analysis was conducted on 298 patients with ACS admitted to the Sixth Affiliated Hospital of South China University of Technology from March 2024 to December 2025. According to the Global Registry of Acute Coronary Events (GRACE) score, patients were divided into low-risk (n=209), intermediate-risk (n=67), and high-risk (n=22) groups. Univariate analysis and multiple linear regression were used to explore the associations of CMI and NT-proBNP with early risk. Spearman correlation analysis was applied to examine the correlations of CMI and NT-proBNP with early risk. Receiver operating characteristic (ROC) curves were used to assess the predictive efficacy of CMI combined with NT-proBNP for intermediate- and high-risk patients.
resultsBaseline data analysis showed that CMI and NT-proBNP levels in the high-risk group were significantly higher than those in the intermediate- and low-risk groups ( P < 0.001). Spearman correlation analysis indicated that CMI and NT-proBNP were positively correlated with early risk in ACS patients. Multiple linear regression models revealed that CMI and NT-proBNP were independent influencing factors for early risk. The ROC curve showed that the area under the curve (AUC) of CMI combined with NT-proBNP for identifying intermediate- and high-risk patients was 0.782 (95% CI: 0.718-0.847), with an optimal cut-off value of 0.3, a sensitivity of 74.2%, and a specificity of 83.7%.
conclusionCMI and NT-proBNP are positively correlated with early risk in ACS patients and serve as independent influencing factors. The combination of CMI and NT-proBNP demonstrates good predictive value for intermediate- and high-risk ACS patients.
Indexed as
Identifiers
42919168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.